Abstract: The present invention provides angiogenic vasculature homing molecules that bind to NG2/HM proteoglycan, including, for example, a peptide comprising the amino acid sequence TAASGVRSMH (SEQ ID NO:1) or LTLRWVGLMS (SEQ ID NO:2). The invention also provides conjugates comprising an angiogenic vasculature homing molecule linked to a moiety such as a drug, a cytotoxic agent, a chemotherapeutic agent, or a detectable agent. The invention additionally provides a method of targeting angiogenic vasculature in a tumor in vivo by contacting the angiogenic vasculature with an angiogenic vasculature homing molecule that selectively homes to a NG2/HM proteoglycan, wherein the angiogenic vasculature homing molecule is not an antibody.
Type:
Grant
Filed:
February 16, 1999
Date of Patent:
March 4, 2003
Assignee:
The Burnam Institute
Inventors:
Michael A. Burg, Renata Pasqualini, Wadih Arap, Erkki Ruoslahti, William B. Stallcup